Sunil Patel

Sunil Patel is a declared insider at 3 companies (board member); the most frequent names are Ligand Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc and OmniAb, Inc. Between 7 October 2010 and 30 January 2023, the trades on record add up to 61 filings.

In open-market terms, that means 21 purchases worth €416k on one side and 11 sales worth €9.8M on the other. The net balance comes to €9.4M on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 22 share grants and 6 option exercises.

In size, the median ticket on the buying side is €3,426. On 2 out of 3 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. Ninety days after publication, 20 purchases show a median change of +7.9%, with the price up in 70% of them. These figures describe past trades and do not predict future prices.

On 1 February 2023 came the latest disclosure, a share grant in OmniAb, Inc. The last insider purchase was made public on 10 November 2022, 1,460 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.